This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated LAMP1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-LAMP1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~44.9 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Adrenal gland (IHC candidate; verify WB) +4 more | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Glycosylated + Cleaved | |
| Caveat | Glycosylation affects migration | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 2 isoform(s) |
The PA1822 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Target-positive lysate and matched negative control (standard starting point) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | PA1822; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
LAMP1 is predicted at 44.9 kDa; glycosylation and signal peptide cleavage could alter migration, but no observed band size is supplied.
| Band near 44.9 kDa | Near the predicted precursor mass; identity needs confirmation |
| Band above 44.9 kDa | May reflect extensive N-linked glycosylation; its migration is not established here |
| Smear or broad band | May reflect heterogeneous N-linked glycosylation |
| Smaller band | May reflect cleavage of the 1–28 signal peptide; identity needs confirmation |
| Predicted precursor mass | 44.9 kDa is the sequence-based reference, not a validated band position |
| N-linked glycosylation at Asn-37 and other sites | Can increase apparent size if the sites are occupied |
| Polylactosaminoglycan N-linked sites at Asn-62 and Asn-121 | May contribute to variable apparent size if modified |
| Signal peptide at residues 1–28 | Cleavage makes the mature protein smaller than the precursor |
| Isoforms 1 and 2 | Sequence differences may affect size, but distinct migration is not established |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | N-linked glycosylation may affect migration | Compare untreated and deglycosylated samples with a validated LAMP1 antibody |
| Band lower than expected | Signal peptide cleavage may reduce size | Check antibody epitope and compare with a verified LAMP1 control |
| Broad smear instead of sharp band | Heterogeneous N-linked glycosylation is possible | Compare untreated and deglycosylated samples |
| Multiple bands | Isoforms 1 and 2 or differing glycosylation may contribute | Check antibody specificity and compare with LAMP1-depleted material |
| Weak or no signal | LAMP1 is a lysosome and endosome membrane protein | Check membrane protein recovery, transfer, and a positive control |
| Fragments below expected size | The supplied features do not identify these fragments | Check sample integrity and antibody specificity with a LAMP1-depleted control |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | High | Protein (IHC) | HPA → |
| Appendix | glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skeletal muscle | myocytes | Low | Protein (IHC) | HPA → |
| Adipose tissue | adipocytes | Medium | Protein (IHC) | HPA → |
| Smooth muscle | smooth muscle cells | Medium | Protein (IHC) | HPA → |
| Soft tissue | fibroblasts | Medium | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | High | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for LAMP1, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Three the supplier anti-LAMP1 antibodies are listed with Western blot images. The supplied evidence includes an A431 lysate blot, an EL4 lysate blot at 1 and 2 μg/mL, and a publication reporting LAMP1 blots in SGJ-treated BMSCs. These examples establish tested contexts, not broader validation.
Which to pick: For human samples, PA1822 and M00780 list human reactivity; M00780 shows an A431 lysate blot. For mouse or rat, A00780 is the only listed option with that reactivity, and its image shows an EL4 lysate blot at 1 and 2 μg/mL.